We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
When Novartis said in June that it would spin off its long-struggling eye-care unit, Alcon, CEO Vas Narasimhan declined to estimate what the valuation on such a transaction might be.